iSTAR Medical initiates international STAR-VI trial for the use of MINIject in conjunction with cataract surgery
- MINIject® is the only commercially available MIGS implant targeting the supraciliary space
- Clinical data show positive, consistent results up to two-year follow-up in patients across Europe, Asia, and Central and South America
- STAR-VI trial extends the body of clinical evidence with the use of MINIject in conjunction with cataract surgery
- Study to be conducted at up to seven sites internationally
WAVRE, Belgium — 15 March 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced that the first patients have been implanted in its STAR-VI international trial evaluating the safety and efficacy of MINIject® in conjunction with cataract surgery in patients with primary open-angle glaucoma.
iSTAR Medical’s STAR-VI trial is a prospective, interventional, multi-center, single-arm study which seeks to implant a total of 30 patients at up to seven sites in Europe and in Central America. Patients will be followed for two years after their cataract surgery and concurrent MINIject® implantation. The primary endpoint of the trial is to measure the proportion of patients achieving a ≥20% reduction in diurnal intraocular pressure (IOP) from baseline to six-month follow-up, regardless of the use of IOP lowering medication.
MINIject® is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) device and is currently the only commercially available supraciliary MIGS implant.
Prof. Iqbal Ike K. Ahmed, Department of Ophthalmology and Visual Sciences, University of Utah (USA), and Chief Innovation Officer, Prism Eye Institute, Ontario (Canada), an investigator in the STAR-VI trial commented: “In the STAR series of trials, iSTAR Medical has established a consistent safety and efficacy profile for standalone use of MINIject in patients with open-angle glaucoma, harnessing the power of the supraciliary space. It is exciting to be involved with this new study, STAR-VI, to assess MINIject’s safety and efficacy also in combination with cataract surgery.”
Mr Mahmoud Radwan, Consultant Ophthalmologist at The Colchester Eye Centre, Colchester (UK),an investigator in the STAR-VI trial commented: “It has been estimated1 that about one in five people undergoing cataract surgery also have glaucoma or ocular hypertension. The ability to treat patients for both cataracts and glaucoma at the same time benefits the patient, the surgeon, the health system as well as society through the efficiency of addressing two major causes of blindness concurrently, and by minimising patient recovery time and cost. I am pleased to be able to take part in the Company’s journey with MINIject to improve the lives of glaucoma patients undergoing cataract surgery.”
Michel Vanbrabant, CEO of iSTAR Medical, commented:“The initiation of our global STAR-VI trial is an important step to bring MINIject to more patients around the world, including to those with co-existing ocular conditions. We are committed to delivering our breakthrough eye care solutions to patients globally and look forward to reporting clinical data from this study in due course.”
- Ends –
For more information
Paul van Hagen
Chief Financial Officer, iSTAR Medical
+32 10 771 244
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Kris Lam
About iSTAR Medical
iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject®, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness – and we are aiming to seek market approval in the US. We believe MINIject®’s distinctive tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of potentially leading products such as MINIject® to establish new treatment paradigms in eye care conditions with the highest patient needs.
MINIject® is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.
Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.2,3 IOP reduction, through medication or surgery, helps delay disease progression.4 Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.3,4 Invasive surgery can present risks with irreversible complications and often requires long-term patient management.3,4 MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.3 MINIject is potentially best-in-class for its promising long-term efficacy and safety.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
COMPLETION OF DIRECTED ISSUE OF 11,577,957 NEW B SHARES AND 250,000 EXISTING TREASURY B SHARES24.3.2023 00:50:07 CET | Press release
Ambu A/S (“Ambu” of the “Company”) has completed its offering of new B shares and existing treasury B shares (together the “Shares”) through an accelerated bookbuilding process (the “Offering”). Further to company announcement no. 6 of 24 March 2023, Ambu has successfully completed an accelerated bookbuild offering of 11,577,957 new B shares and 250,000 existing treasury B shares (in aggregate corresponding to approximately 5.3% of Ambu’s issued B shares), at a sales price of DKK 93 per share, raising gross proceeds to the Company of approximately DKK 1.1 billion. The board of directors of Ambu (the "Board") has today exercised its authorization in Article 9e(2) in Ambu’s Articles of Association, pursuant to which the Board is authorised to make share capital increases without pre-emption rights for the existing shareholders at a price not lower than market price, to increase Ambu's share capital by issue of 11,577,957 new B shares at a subscription price of DKK 93 per new B share. The
Årsrapport 202223.3.2023 22:58:17 CET | pressemeddelelse
Selskabsmeddelelse nr. 2 – 2023 København, den 23. marts 2023 Årsrapport 2022 Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2022. Årsrapporten har følgende hovedpunkter: NTR Holding koncernens salg af Daniamant A/S og Daniamant Ltd. blev gennemført den 31. januar 2022. Hovedparten af provenuet fra salget af Daniamant er udbetalt som udbytte. NTR Holding A/S har således i 2022 udbetalt udbytte på i alt DKK 49 pr. aktie, svarende til et samlet udbytte på DKK 121 mio. Bestyrelsen foreslår, at der ikke udloddes yderligere udbytte for 2022. Koncernens resultat af primær drift udviser et underskud på DKK 2,5 mio. (DKK -1,9 mio. i 2021), hvilket er i overensstemmelse med de senest udmeldte resultatforventninger. Koncernens totalindkomst udgør DKK 1,1 mio. Egenkapitalen udgør DKK 12,9 mio., svarende til en indre værdi pr. aktie på DKK 5,2. Bestyrelsen vil fortsat sondere NTR Holding A/S’ strategiske muligheder, herunder for at kapitaliser
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting23.3.2023 22:40:00 CET | Press release
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting Luxembourg, March 23, 2023 – The Nomination Committee of Millicom International Cellular S.A. (“Millicom”) announces that Mr. Nicolas Jaeger appointed by Atlas Luxco S.àr.l., has joined the Nomination Committee of Millicom. On March 17, 2023, Atlas Luxco S.àr.l. reported that it holds a 20% shareholding in Millicom. On March 23, 2023 Mr. Nicolas Jaeger joined the Nomination Committee. The Nomination Committee comprises Jan Dworsky, appointed by Swedbank Robur Funds; Viktor Kockberg, appointed by Nordea Investment Funds; Staley Cates, appointed by Southeastern Asset Management, Gerardo Zamorano appointed by Brandes Investment Partners, and Nicolas Jaeger appointed by Atlas Luxco S.àr.l., as well as the Chairman of Millicom’s Board of Directors, José Antonio Ríos García. Information about the work of the Nomination Committee can be found on Millicom’s website. Shareholders wishing to p
GreenMobility issues warrants23.3.2023 22:40:00 CET | Press release
Company Announcement no. 121– 2023 Copenhagen, March23rd, 2023 GreenMobility issues warrants The Board of Directors of GreenMobility A/S S (“GreenMobility” or the “Company”), has today resolved to grant warrants in the Company for the purpose of: Ensuring that shareholders, the Executive Management and other management employees of the Company have the same interests, and that everyone makes a special effort for the value creation in the Company and its subsidiaries.Retaining the Executive Management and management employees of the Company.Granting warrants to the Board of Directors as authorized at the 2021 Annual General Meeting but not yet granted Warrants granted will generally be subject to the existing warrant programs as publicized in company announcement no. 41 on November 19th, 2019 and in company announcement no. 64 on September 29th 2020 with certain deviations. The total issuance of warrants is in accordance with the resolutions passed at the Annual General Meetings held on
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results23.3.2023 22:00:00 CET | Press release
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023. Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023, at8:00 am (New York)